Clinical trial · Interventional
Assessment of the Minimal Residual Disease in DLBCL From Cell-free Circulating DNA by NGS
Assessment of the Minimal Residual Disease in Diffuse Large B-Cell Lymphomas (DLBCL) From Cell-free Circulating DNA by Next Generation Sequencing (NGS)
NCT02339805CI-TRIAL-00028517LymphoSeqcompletedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a prospective descriptive monocentric study whose purpose is to describe the clonal evolution of the mutational pattern in cfDNA of a cohort of patients with Diffuse Large B-Cell Non-Hodgkin Lymphomas (DLBCL) before, during and after standard treatment
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non Hodgkin Lymphoma | Non-Hodgkin Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Fluorine-18 fluorodeoxyglucose positron emission tomography (18F-FDG-PET) | Device | — | UNRESOLVED |
| next generation sequencing | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- next generation sequencing
- description
- Determination of clonotypic evolution of the minimal residual disease by next generation sequencing.
- interventionNames
- Other: next generation sequencing
- Device: Fluorine-18 fluorodeoxyglucose positron emission tomography (18F-FDG-PET)
Primary outcomes (1)
- measure
- Determine the clonal evolution during and after treatment by Next Generation Sequencing
- timeFrame
- one year
- description
- DNA from tumor, DNA from peripheral blood and DNA from bone marrow will be sequencing by NGS for a panel of 34 genes.
Secondary outcomes (4)
- measure
- Progression free survival
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age up to 18 years old * With a diagnosis formally established of DLBCL or transformed straightaway follicular lymphoma or 3B grade follicular lymphoma or Burkitt-like lymphoma * Eligible to a treatment by immunochemotherapy like R-CHOP, R-ACVBP or R-CHOP like * First line of treatment * Being able to benefit from standard extension assessment ( Fluorine-18 fluorodeoxyglucose positron emission tomography (18F-FDG-PET) and bone marrow biopsy with a bone marrow aspiration) * Written informed consent * Tumor biopsy used for diagnosis available Exclusion Criteria: * Patient who cannot receive polychemotherapy like R-CHOP, R-ACVBP, or R-CHOP like * Patient who cannot benefit from standard extension assessment and follow-up by with Fluorine-18 fluorodeoxyglucose positron emission tomography (18F-FDG-PET) * Pregnant or breast-feeding woman * Guardianship, curatorship * Patient who cannot follow the medical procedures of the study for geographic, social, psychological,linguistic or physical reasons
References
Publications (1)
- DERIVEDCamus V, Sarafan-Vasseur N, Bohers E, Dubois S, Mareschal S, Bertrand P, Viailly PJ, Ruminy P, Maingonnat C, Lemasle E, Stamatoullas A, Picquenot JM, Cornic M, Beaussire L, Bastard C, Frebourg T, Tilly H, Jardin F. Digital PCR for quantification of recurrent and potentially actionable somatic mutations in circulating free DNA from patients with diffuse large B-cell lymphoma. Leuk Lymphoma. 2016 Sep;57(9):2171-9. doi: 10.3109/10428194.2016.1139703. Epub 2016 Feb 17. PMID 26883583